Investment
Features
FeesSafety
Academy
More
Pluang+

PENN Entertainment holds steady with $18 target amid mixed earnings and debt concerns.

Analyst Insights
14 Sep 2026
Seeking Alpha
View Source
Neutral
PENN Entertainment holds steady with $18 target amid mixed earnings and debt concerns.

PENN Entertainment maintains a Hold rating with an $18 price target due to mixed Q2 earnings and limited valuation upside compared to peers. The retail segment showed solid growth with a 5.6% increase in adjusted EBITDAR, especially strong in the Midwest and West regions. However, the Interactive segment's revenue growth has slowed sharply despite improving profitability, raising concerns about long-term competitiveness. The company remains highly leveraged with net debt around 5.2x–5.5x, making proactive debt reduction and consistent Interactive profitability key factors to watch going forward.

More News

Trump warns South Korea to join $50B Alaska LNG project or face higher costs, amid investment deal confusion.

Trump warns South Korea to join $50B Alaska LNG project or face higher costs, amid investment deal confusion.

U.S. President Donald Trump warned South Korea to sign on soon to the $50 billion Alaska LNG project or face higher charges, possibly tariffs, though he did not specify details. South Korea is still evaluating the project based on commercial viabilit...

Market News
Neutral
4 hours ago
Zcash hires lobbyist to influence US crypto policies, boosting Bitcoin price outlook for 2026

Zcash hires lobbyist to influence US crypto policies, boosting Bitcoin price outlook for 2026

Zcash has registered a lobbyist in Washington, DC, aiming to influence US cryptocurrency policies, including tax rules and market structure. This move is part of Zcash's effort to promote privacy-focused crypto regulations. Market watchers see this a...

Market News
Bullish
4 hours ago
CSL inks $1.6B deal to develop rare kidney and liver disease drug lixudebart

CSL inks $1.6B deal to develop rare kidney and liver disease drug lixudebart

CSL Limited has signed an exclusive licensing deal with Swiss biotech Alentis Therapeutics to develop and commercialize lixudebart, a drug in Phase 2 trials for rare autoimmune kidney disease ANCA-associated vasculitis. The drug targets inflammation ...

Company Fundamentals
Bullish
4 hours ago
GraniteShares 2x Long MU ETF rated Hold amid near-term volatility despite Micron's strong long-term outlook

GraniteShares 2x Long MU ETF rated Hold amid near-term volatility despite Micron's strong long-term outlook

GraniteShares 2x Long MU Daily ETF (MULL), which offers double the daily performance of Micron stock, is rated Hold due to expected short-term volatility. Micron's growth prospects remain strong, supported by expanding production capacity, high deman...

Market News
Neutral
4 hours ago
Ether short position on Hyperliquid shows $30M unrealized loss amid market moves

Ether short position on Hyperliquid shows $30M unrealized loss amid market moves

A wallet holding a large short position of about 78,000 Ether (ETH) on Hyperliquid experienced an unrealized loss of approximately $30.29 million as of October 5. The position was valued at around $213 million with an average opening price of $2,340 ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App